Exploring user and stakeholder perspectives from South Africa and Uganda to refine microarray patch development for HIV PrEP delivery and as a multipurpose prevention technology.

Ayesha IsmailSarah MagniAnne KatahoireFlorence AyebareGodfrey SiuFred SemitalaPeter KyambaddeBarbara FriedlandCourtney Jarrahian Maggie Kilbourne-Brook

Published in: PloS one (2023)

Potential users and stakeholders showed strong interest in/acceptance of MAP technology, and their feedback identified key improvements for MAP design. If a MAP containing a high-potency antiretroviral or a MAP containing both an antiretroviral and hormonal contraceptive is developed, these products could improve acceptability/uptake of protection options in sub-Saharan Africa.

Keyphrases

hiv positive
hiv infected
men who have sex with men
south africa
human immunodeficiency virus
hiv aids
antiretroviral therapy
high density
hiv testing
metabolic syndrome
human health
climate change